IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 0 5 2007

In re Applicant:

Iris PECKER et al

Serial No.:

10/676,079

Filed:

02-Oct-2003

For:

HEPARANASE SPECIFIC MOLECULAR

PROBES AND THEIR USE IN RESEARCH

AND MEDICAL APPLICATIONS

Examiner:

DIBRINO, MARIANNE NMN

Group Art Unit: 1644

Attorney

Docket: 26871

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement is being filed subsequent to an Office Action being mailed and a late fee of \$180 is due. Please charge my Deposit Account 50-1407 for this fee, as well as any additional fees due.

This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

> 01/08/2007 JADDO1 00000016 501407 10676079

01 FC:1806 180.00 DA

Respectfully submitted,

Martin D. Moynihan Registration No. 40,338

Dated: January 2, 2007

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Substitute for form 1449A/PTO

 Complete if Known

 Application Number
 10/676,079

 Filing Date
 May 1, 1998

 First Named Inventor
 PECKER Iris et al

 Art Unit
 1644

 Examiner Name
 DIBRINO, MARIANNE NMN

Sheet 1 of 4 Attorney Docket Number 26871

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code ^{2 (if known)}			Figures Appear	
	1	US-6,230,151	08-8-2001	Agrawal et al.		
	2	US-5,799,311	08-25-1998	Agrawal et al.		
	3	US-6,314,420	06-6-2001	Lang et al.		
	4	US-4,937,747	06-26-1990	Koller		
_	5	US-6,307,965	10-23-2001	Aggarwal et al.		
	6	US-6,226,792	01-1-2001	Goiffon et al.		
	7	US-5,859,929	01-12-1999	Zhou et al.		
	8	US-5,799,276	08-25-1998	Komissarchik et al.		
	9	US-2002/0068061	06-6-2002	Peretz et al.		
	10	US-5,360,735	01-1-1994	Weinshank et al.		
	11	US-2002/0088019	04-4-2002	Yacoby-Zeevi		
	12	US-5,589,604	12-31-1996	Drohan et al.		
	13	US-5,700,671	12-23-1997	Prieto et al.		
	14	US-5,714,345	03-3-1998	Clark		
	15	US-5,716,817	02-10-1998	T?rnell		
	16	US-6,140,552	10-31-2000	Deboer et al.		
	17	US-2003/0163836	08-28-2003	Garofalo et al.		
	18	US-2002/0194625	12-19-2002	Zcharia et al.		
	19	US-6,190,875	02-20-2001	Ben-Artzi et al.		
	20	US-2001/0006630	05-5-2001	Yacobi-Zeevi et al.		
-	21	US-2002/0114801	08-22-2002	Pecker et al.		
	22_	US-6,475,763	05-5-2002	Ayal-Hershkovitz et al.		
	23	US-6,426,209	07-30-2002	Ayal-Hershkovitz et al.		
	24	US-6,800,441	05-5-2004	Pecker et al.		
	25	US-2002/0168749	11-14-2002	Pecker et al.		
	26	US-2003/0068806	04-10-2003	Ayal-Hershkovitz et al.		
	27	US-6,946,131	09-20-2005	Peretz et al.		
	28	US-2003/0181687	09-25-2003	Peretz et al.		
	29	US-6,960,471	01-1-2005	Pecker et al.		
_	30	US-2003/0190737	09-9-2003	Pecker et al.		
	31	US-2003/0170860	09-11-2003	Pecker et al.		
	32	US-2003/0217375	11-20-2003	Zcharia et al.		
	33	US-2004/0213789	10-28-2004	Yacobi-Zeevi et al.		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		Substitute for form 1449A	VPTO	Complete if Known			
		Substitute for form 14437	VFIO	Application Number	10/676,079		
		SUPPLEMENT	'AL	Filing Date	May 1, 1998		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					First Named Inventor	PECKER Iris et al 1644 DIBRINO, MARIANNE NM	
					Art Unit		
(use as many sheets as necessary)				Examiner Name			
Sheet	et 2		of	4	Attorney Docket Number	2687	71
			U.S.	PATENT	DOCUMENTS		
	34	US-2004/0146497	07-29-20	004	Ilan et al.		
	35	US-6,986,996	01-17-20	006	Pecker et al.		
	36	US-2004/0146925	07-29-20	004	Pecker et al.		
	37	US-2005/0260187	11-24-20	005	Ilan et al.		
	38	US-2006/0008892	01-12-20	006	Yacobi-Zeevi et al.		
	39	US-2003/0031660	02-13-20	003	Yacobi-Zeevi et al.		
							ĺ

		FOREIGN	PATENT DOC	UMENTS			
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY		of Patentee or of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
	40	PCT WO 00/03036	01-20-2000	Ben-Artz	i et al.		T
	41	PCT WO 00/25817	05-11-2000	Peretz et al.			Т
	42	PCT WO 92/01003	01-23-1992	Nicolson et al.			T
,	43	PCT WO 02/32283	04-25-2002	Yacoby-Zeevi			T
	44	PCT WO 02/19962	03-14-2002	Ilan et al.			T
	45	AU 735116	06-28-2001	Pecker et al.			
	46	AU 768820	08-8-2004	Ben-Artz	i et al.		1
	47	PCT WO 2004/108065	12-16-2004	Yacobi-Z	eevi et al.		T
	48	PCT WO 99/18852	04-22-1999	Arenson			F
Examiner Signature		L.			Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Under the Paperv	work Reduction	Act of 1995, no persons are required	to respond to	a collection of information unless it contain					
	Sul	ostitute for form 1449A/PTO		Complete if Known					
	501			Application Number	10/676,079				
	SUP	PLEMENTAL		Filing Date	May 1, 1998				
TNIE		TION DISCLOSUR	10	First Named Inventor	PECKER Iris et al				
				Group Art Unit	1644				
STATEMENT BY APPLICANT				Examiner Name	DIBRINO, MARIAN	INE NMN			
	(use as ma	ny sheets as necessary)							
Sheet	3	Of	4	Attorney Docket Number	26871	-			
		OTHER PRIOR	ART – NO	ON PATENT LITERATURE D	OCUMENTS				
Examiner	Cite	Include name of the author (in CAPITA	L LETTERS), title of the article (when	appropriate), title of the				
Initials	No.1			mposium, catalog, etc.) date, page(s), v	olume-issue number(s),	T ²			
				ity and/or country where published.					
	49	Miyake et al. "Highly Specific and Sensitive Detection of Malignancy in Urine							
				thelial Cancer by CD44v8-10/C					
		Competitive RT-PCR", Int. J. Cancer, 79(6): 560-564, 1998. Abstract.							
	50	Marra et al. ""The WashU-HHMI Mouse EST Project", Database EMBL, Accession							
		No. Al122034, XP 002198426, 1998. Abstract.							
	51	Zcharia et al. "Heparanase Regulates Murine Hair Growth", American Journal of							
	1	Pathology, 166(4): 999-							
	52	Zhu et al. "Development of Heritable Melanoma in Transgenic Mice", The Journal of							
		Investigative Dermatology, 110: 247-252, 1998.							
	53	Duff "Transgenic Mice Overexpressing Presentlin cDNAs: Phenotype and Utility in							
				ease", Central Nervous System					
	İ	2000. Abstract.		,	, , ,				
	54	Doetschman "Interpretation of Phenotype in Genetically Engineered Mice",							
		Laboratory Animal Scie			,				
					re" Theriogenology				
		Wall "Transgenic Livestock: Progress and Prospects for the Future", Theriogenology, 45: 57-68, 1996.							
	56		t Hyperte	ension in Transgenic Rats Harbe	ouring the Mouse				
	30	Mullins et al. "Fulminant Hypertension in Transgenic Rats Harbouring the Mouse Ren-2 Gene", Nature, 344: 541-544, 1990.							
	57	Hammer et al. "Spontaneous Inflammatory Disease in Transgenic Rats Expressing							
	"			Animal Model of HLA-B27-Ass					
					ociated Huillall				
	50	Disorders", Cell, 63: 1099-1112, 1990.							
	58	Taurog et al. "HLA-B27 in Inbred and Non-Inbred Transgenic Mice", The Journal of							
<u> </u>		Immunology, 141(11): 4							
	59	Pearce et al. "Development of Glucose Intolerance in Male Transgenic Mice							
				Synthase Kinase-3? on A Mus	scle-Specific				
		Promoter", Metabolism,	53(10): 1	322-1330, 2004.					
				-					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Signature

Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03) Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pap	erwork Reductio	n Act of 1995, no persons are required to respond to a collection						
	Su	ubstitute for form 1449A/PTO	Complete if Known					
	a	TIMBE BRESSER AT	Application Number	10/676,079				
		UPPLEMENTAL	Filing Date First Named Inventor	May 1, 1998				
	INFORM	MATION DISCLOSURE	Group Art Unit	PECKER Iris et al				
	STATE	MENT BY APPLICANT	Examiner Name	DIBRINO, MARIANNE				
		as many sheets as necessary)	Examiner Name	NMN				
Sheet	4	Of 4	Attorney Docket Number	26871				
		OTHER PRIOR ART – NON PATEN	T LITERATURE DOC					
	60	Li et al. "In Vivo Fragmentation of Hepara	n Sulfate by Heparanas	e				
	1	Overexpression Renders Mice Resistant to	Amyloid Protein A Am	nyloidosis",				
		PNAS, 102(18): 6473-6477, 2005.						
	61	Zcharia et al. "Heparanase Acclerates Wound Angiogenesis and Wound Healing						
	ļ	in Mouse and Rat Models", The FASEB Jo						
	62	Zcharia et al. "Molecular Properties and In						
		Progression and Mammary Gland Morpho		mmary Gland				
	- 162	Biology and Neoplasia, 6(3): 311-322, 200		- Dethans				
	63	Nadir et al. "Co- Interaction and Increased						
	64	Inhibitor by Heparanase", Blood, 106(11/F Spiegel et al. "Heparanase Facilitates Deve						
i	04	Migration of Hematopoietic Stem and Pro						
		826a, 2003. Abstract# 3056.	genitor cens, blood, is	02(11). 6254-				
	65	Zcharia et al. "Transgenic Expression of M	lammalian Henaranase	Uncovers				
	00	Physiological Functions of Heparan Sulfat						
		Vascularization, and Feeding Behavior", T						
	66	Nasser et al. "Heparanase Neutralizes the						
		and Low-Molecular-Weight Heparin", Jou						
		4: 560-565, 2006.						
	67	Mullins et al. "Expression of the DBA/2J I		nal Gland of				
,		Transgenic Mice", The EMBO Journal, 8(
	68	McKenzie et al. "Biochemical Characteriz						
		of Human Heparanase (Hpa1) Protein Exp	ressed in Insect Cells",	Biochemical				
	- 100	Journal, 373: 423-435, 2003.	4 '-11 (T) 3 1'-					
	69	Nakajima "Heparanases and Tumor Metas	tasis", Tanpakushitsu K	akusan Koso,				
	70	37(11): 1753-1758, 1992. Abstract. Ricoveri et al. "Heparan Sulfate Endoglyce	osidose and Matastatic I	Optontial in				
	'0	Murine Fibrosarcoma and Melanoma", Ca						
		1986. Abstract.	11001 Research, 40(0). 30	333-3601,				
	71	Hatano et al. "Biologic Activities of Antob	odies to the Neutral-Po	lysaccharide				
	1 ' '	Component of the Pseudomonas Aerugino						
		O Side Chains and Mucoid Exopolysaccha						
		63(1): 21-26.	, , , , , , , , , , , , , , , , , , , ,					
	72	Vernet et al. "Virulence Factors (Aerobact						
		Klebsiella Pneumoniae and Escherichia Co	oli Blood Culture Isolate	es", FEMS				
		Microbiol. Lett., 130(1): 51-57, 1995. Abs	tract.					
	73	Elkin et al. "Heparanase as Mediator of Ar	ngiogenesis: Mode of A	ction", The				
		FASEB Journal, 15: 1661-1663, 2001.						
	74	Cheng et al. "Increased Sulfation of Glyco						
		Epithelia Cells From Patients With Cystic	Fibrosis", Journal of Cl	inical				
		Invetment, 84(1): 68-72, 1989. Abstract.						

Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.